Inaugural chair Dr. Blase Polite recaps the productive first year of ASCO’s Health Policy Committee, which works to ensure that ASCO remains a leading advocate for a cancer care system that protects p
Experts discuss the current standard of care for patients with EGFR–wild-type locally advanced non–small cell lung cancer.
Increasing evidence demonstrates that approximately one-half of patients with high-risk or locally advanced cutaneous squamous cell carcinoma achieve a pathologic complete response following 2 to…
Ruth Porat, President and Chief Investment Officer of Alphabet Inc. and its subsidiary, Google, will highlight the potential of artificial intelligence and machine learning to…
Use of local vaginal estrogen to treat menopausal symptoms related to antihormonal treatment does not compromise overall or breast cancer–specific survival in women 65 years…
Upon its launch in 2015, the TAPUR study employed a novel approach of evaluating additional uses of oncology drugs outside of indications already approved by…
The new penile cancer guidance was designed to be comprehensive, addressing every aspect of care from diagnosis to treatment and follow-up, with a patient-centered approach.
ASCO has issued new clinical guidance for best treating patients with gastrointestinal (GI) cancer amidst a nationwide shortage of carboplatin and cisplatin. The 2 chemotherapy…
ASCO and ACS have announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership will create one…
Cesar Perez: Exciting update in lung cancer treatment being presented at ASCO2025 / ASCO2025, cancer, Cesar Perez, lung cancer treatment, NSCLC, OncoDaily,
A novel triple oral metronomic chemotherapy regimen extends overall survival in the second-line setting compared with standard-of-care options in advanced head and neck cancers, according…
